But, like Merck two weeks ago, GSK has failed to hit overall survival.
ApexOnco Front Page
Recent articles
Two Kelun ADCs and two actinium-based radioconjugates start phase 1.
The company reports an “unprecedented” 100% PSA50 rate with JANX007, but in a small, selected number of patients.
Myelofibrosis projects and Merck's ROR1 ADC fight for attention at this month's conference.
Amid a KRAS data dump, a doublet of RMC-6236 and RMC-6291 was a highlight.
Party season approaches; but first, conferences.
Two cast-offs comprise the private group's attempts to hit PARP1 and PARP7.
A $1bn buyout gives Roche more allogeneic Car-T projects, plus non-viral gene therapy contenders.
